# Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

> **NCT00051909** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 200 (—)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** LY451395

## Key facts

- **NCT ID:** NCT00051909
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2003-06
- **Target enrollment:** 200 (—)
- **Last updated:** 2006-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00051909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00051909, "Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00051909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*